Here's a classic biotech story: a company announces promising clinical trial results for a new drug, and then—almost immediately—announces it needs to sell more stock to keep the development going. That's what's happening with Incannex Healthcare Limited (IXHL) today, and its shares are taking the predictable hit.

The clinical-stage biotech said it's doing a registered direct offering to raise $10 million. It's selling 2 million shares, plus warrants to buy another 2 million shares, all at a combined price of $5. If investors decide to exercise all those warrants for cash later, the company could get another $13 million. That's a potential total of up to $23 million in new money.

So what's the money for? To finish the next study for its lead drug candidate, a treatment for obstructive sleep apnea called IHL-42X. The company is calling this next step the "DReAMzz Phase 2 crossover study." Incannex also said it's shutting down its at-the-market (ATM) equity facility and doesn't plan to use that kind of financing anytime soon.

This all comes right after Incannex laid out an updated clinical strategy for IHL-42X, following what it says were positive Phase 2 results. The drug has Fast Track Designation from the FDA, which is meant to speed up the review of treatments for serious conditions.

The Phase 2 trial, called RePOSA, showed what the company calls statistically significant improvements. In the study, 33.3% of patients on a low dose and 41.2% on a high dose saw their apnea-hypopnea index (a key measure of sleep apnea severity) drop by more than 30%. Even more impressive, 13.9% and 14.7% of those groups, respectively, saw reductions greater than 50%.

Now, the plan is to run a new Phase 2 study to fine-tune the dose. This "crossover dose-optimization" study will test different ratios of the drug's two active ingredients, dronabinol and acetazolamide. The idea is to get the formula just right before moving into a more streamlined, and expensive, Phase 3 program. The company expects to start dosing patients in this new study soon.

For investors, the math is simple: promising science often requires more capital. The market's reaction was just as straightforward. According to market data, Incannex Healthcare shares were down 37.48% at $3.73 at the time of publication on Thursday.